High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$26.0M
$26,005,146
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Ragosa Mark
• CFO
10b5-1 SellΔOwn -36.8%
2026-03-09
$1,686,158Largex2
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
10b5-1 SellΔOwn -36.8%
|
2026-03-09 | $1,686,158Largex2 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Paolini John F.
• Officer • CHIEF MEDICAL OFFICER
10b5-1 Sell
2026-03-02
$1,792,940Largex3
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 Sell
|
2026-03-02 | $1,792,940Largex3 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
10b5-1 SellΔOwn -17.7%
2026-02-12
$121,050
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
10b5-1 SellΔOwn -17.7%
|
2026-02-12 | $121,050 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
10b5-1 Sell
2026-02-10
$4,950
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
10b5-1 Sell
|
2026-02-10 | $4,950 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Ragosa Mark
• CFO
10b5-1 SellΔOwn -30.4%
2026-02-09
$772,254x2
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
10b5-1 SellΔOwn -30.4%
|
2026-02-09 | $772,254x2 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
10b5-1 SellΔOwn -17.2%
2026-02-04
$117,142
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
10b5-1 SellΔOwn -17.2%
|
2026-02-04 | $117,142 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
10b5-1 SellΔOwn -50.0%
2026-02-03
$567,143
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
10b5-1 SellΔOwn -50.0%
|
2026-02-03 | $567,143 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
10b5-1 Sell
2026-02-02
$37,350
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
10b5-1 Sell
|
2026-02-02 | $37,350 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Ragosa Mark
• CFO
10b5-1 SellΔOwn -38.6%
2026-01-08
$502,680
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
10b5-1 SellΔOwn -38.6%
|
2026-01-08 | $502,680 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Quart Barry D
• Director
10b5-1 SellΔOwn -61.6%
2025-12-15
$835,555
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Director
10b5-1 SellΔOwn -61.6%
|
2025-12-15 | $835,555 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Tessari Eben
• COO
10b5-1 SellΔOwn -42.0%
2025-12-15
$500,715
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 SellΔOwn -42.0%
|
2025-12-15 | $500,715 | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 Sell
|
2025-11-26 | $8,578 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Tessari Eben
• COO
10b5-1 Sell
2025-11-17
$514,224x2
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 Sell
|
2025-11-17 | $514,224x2 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Ragosa Mark
• CFO
10b5-1 SellΔOwn -39.0%
2025-11-12
$814,706
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
10b5-1 SellΔOwn -39.0%
|
2025-11-12 | $814,706 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Paolini John F.
• Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -57.4%
2025-10-31
$3,065,610Large
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -57.4%
|
2025-10-31 | $3,065,610Large | S | Form 4 |
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CFO
10b5-1 Sell
|
2025-10-28 | $4,100 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Patel Sanj K
• CEO
10b5-1 SellΔOwn -46.6%
2025-10-22
$3,781,654Large
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CEO
10b5-1 SellΔOwn -46.6%
|
2025-10-22 | $3,781,654Large | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Patel Sanj K
• CEO
10b5-1 SellΔOwn -26.0%
2025-10-21
$1,524,863Large
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CEO
10b5-1 SellΔOwn -26.0%
|
2025-10-21 | $1,524,863Large | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Megna Michael R
• Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -32.9%
2025-10-20
$1,962,781Largex2
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
Officer • CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -32.9%
|
2025-10-20 | $1,962,781Largex2 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Patel Sanj K
• CEO
10b5-1 SellΔOwn -16.6%
2025-10-20
$4,717,015Largex2
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
CEO
10b5-1 SellΔOwn -16.6%
|
2025-10-20 | $4,717,015Largex2 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Tessari Eben
• COO
10b5-1 Sell
2025-10-14
$465,843x2
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 Sell
|
2025-10-14 | $465,843x2 | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Tessari Eben
• COO
10b5-1 SellΔOwn -54.9%
2025-09-29
$1,609,860Large
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 SellΔOwn -54.9%
|
2025-09-29 | $1,609,860Large | S | Form 4 |
|
KNSA
S
Kiniksa Pharmaceuticals International, plc
Tessari Eben
• COO
10b5-1 Sell
2025-09-15
$597,976x2
|
||||||
| KNSA |
Kiniksa Pharmaceuticals International, plc
|
COO
10b5-1 Sell
|
2025-09-15 | $597,976x2 | S | Form 4 |